A Study Comparing Two Different Capsules, APL-101 and PLB-1001 Capsules, in Healthy Chinese and Caucasian Participants

Bioequivalence Clinical Trial

Official title:

An Open-Label, Multi-Center, Randomized, 2-Way Crossover Study to Assess the Bioequivalence of APL-101 Capsule vs PLB-1001 Capsule in Healthy Chinese and Caucasian Subjects

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05367388
• Other study ID #: APL-101-03
• Status: Recruiting
• Phase: Phase 1
• Start date: May 20, 2022
• Est. completion date: December 2022

Study information

• Verified date: June 2022
• Source: Apollomics Inc.
• Contact: Yufei Chen, MS
• Phone: 650-209-4055
• Email: Yufei.Chen[@]apollomicsinc.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a Phase 1, open-label, multi-center, randomized, 2-period, adaptive design, crossover study to assess the bioequivalence of APL-101 (Vebreltinib) capsules and PLB-1001 (Bozitinib) capsules. The treatments to be administered orally in this study include: - Treatment A (reference): Two 100 mg APL-101 (Vebreltinib) capsules (200 mg dose), manufactured for Apollomics, Inc - Treatment P (test): Two 100 mg PLB-1001 (Bozitinib) capsules (200 mg dose), manufactured for Beijing Pearl Biotechnology Co., Ltd. APL-101 capsules (Treatment A) and PLB-1001 capsules (Treatment P) are similar drug products.

Description:

Up to 48 healthy male subjects (approximately 16 Chinese and approximately 32 Caucasians) will be enrolled in the study in at least 2 sequential cohorts and randomly assigned to 1 of 2 treatment sequences. The treatment sequence will be determined using a 2×2 crossover design. This study includes an adaptive design feature of variable sample size. Data from the first 16 subjects will be used to determine the intra-subject variability to ensure a sufficient total sample size to achieve study objectives. If needed, up to 72 subjects will be enrolled.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 48
• Est. completion date: December 2022
• Est. primary completion date: November 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 18 Years to 55 Years

Eligibility

Major Inclusion Criteria:

• Must be Chinese (1st generation or 2nd generation Chinese with both Chinese parents), or Caucasian.
• Body mass index between 18.0 and 30.0 kg/m2, inclusive.
• In good health, determined by no clinically significant findings from medical history, physical examination, 12 lead ECG, vital sign measurements, and clinical laboratory evaluations at screening and at check-in as assessed by the Investigator (or designee). Screening clinical laboratory evaluations may be repeated once at the discretion of the Investigator.
• Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) = 1.5 × the upper limit of normal (ULN), total bilirubin = 1.5 × ULN at screening and check-in. Subjects with ALT or AST >1.0 × ULN combined with total bilirubin >1.0 × ULN are excluded.
• QT interval corrected for heart rate using Fridericia's method (QTcF) = 450 msec confirmed by calculating the mean of the triplicate measurements within 4 weeks prior to Day 1.
• Systolic blood pressure between 100 and 140 mmHg or diastolic blood pressure between 50 and 90 mmHg, confirmed by calculating the mean of the triplicate measurements within 4 weeks prior to Day 1.

Major Exclusion Criteria:

• Significant history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder, as determined by the Investigator.
• History of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance, unless approved by the Investigator.
• Have positive Coronavirus Disease 2019 (COVID-19) test at screening and/or at check-in, have clinical signs or symptoms of COVID-19 as determined by the Investigator, or have ongoing significant complication(s) from prior COVID-19 infection.
• Use or intend to use any nonprescription medications/products including vitamins, minerals, and phytotherapeutic/herbal/plant derived preparations within 14 days prior to check in, unless deemed acceptable by the Investigator.
• Have previously completed or withdrawn from this study or any other study investigating APL 101 or similar drug product, and/or have previously received APL 101 or similar drug product.

Related Conditions & MeSH terms

• Bioequivalence

Intervention

Drug:
• APL-101
APL-101 (Vebreltinib) is an orally available small molecule, which is a tyrosine kinase inhibitor (TKI) for the mesenchymal epithelial transition protein tyrosine kinase receptor (c-Met) with high selectivity and potency. The treatments to be administered in this study include: • Treatment A (reference): Two 100 mg APL-101 (Vebreltinib) capsules (200 mg dose), manufactured for Apollomics, Inc.
• PLB-1001
PLB-1001 (Bozitinib) is a chemical drug category 1.1 innovative drug. It is a highly effective and highly selective c-Met tyrosine kinase inhibitor. The treatments to be administered in this study include: • Treatment P (test): Two 100 mg PLB-1001 (Bozitinib) capsules (200 mg dose), manufactured for Beijing Pearl Biotechnology Co., Ltd.

Locations

Country	Name	City	State
New Zealand	New Zealand Clinical Research	Auckland

Sponsors (1)

Lead Sponsor	Collaborator
Apollomics Inc.

Country where clinical trial is conducted

New Zealand, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Area under the plasma concentration versus time curve (AUC)	Area under the curve (AUC) from time zero to infinity (AUC0-8) and from time zero to the last quantifiable concentration (AUC0-last)	Day 1 to Day 14
Primary	Maximum observed plasma concentration	Maximum observed plasma concentration (Cmax) after dosing of both treatments	Day 1 to Day 14
Secondary	Time to the maximum observed plasma concentration	Time to the maximum observed plasma concentration (tmax)	Day 1 to Day 14
Secondary	Number of adverse events observed	Number of incidences of adverse events observed with respect to severity and relatedness to study treatment.	Day 1 to Day 20-22
Secondary	Apparent plasma terminal elimination half-life	Apparent plasma terminal elimination half-life (t1/2) after dosing of both treatments	Day 1 to Day 14